Philips, the Dutch multinational corporation, announced on Tuesday that it has reached a preliminary agreement with the U.S. Department of Justice (DOJ) to conclude an investigation regarding the company’s sleep and respiratory care products.
Philips is known for a diverse range of products, extending from consumer electronics like toothbrushes to sophisticated medical imaging systems.
In 2021, Philips’ subsidiary Respironics initiated a massive recall of millions of devices worldwide due to concerns that the foam used in their products might degrade over time, potentially releasing toxic substances and cancer-causing particles. This recall triggered a series of investigations and lawsuits.
Recently, the company achieved a legal victory in a court case in the Netherlands, where shareholders demanded investigations into allegations of misleading disclosures and management negligence connected to the company’s practices.
On Tuesday, Philips announced that its subsidiary Respironics has, in principle, come to an agreement with the U.S. Department of Justice to resolve the previously disclosed investigation.
As part of this agreement, Philips set aside €288 million (approximately $322 million) as a provision for the proposed settlement in the third quarter. However, the settlement still requires final documentation and is expected to be paid in the first quarter of 2027.
The provision represents money the company anticipates it will have to pay for future settlements or compensations. It has already been recorded as a ‘loss/cost’ in the third quarter financials to transparently inform investors about the expected financial impact.
Philips did not disclose whether the agreement included terms that would require the company to admit any wrongdoing.
Roy Jakobs, the CEO of Philips, stated during a conference call discussing the financial results that, “At this point, we cannot provide qualitative details,” and further noted that the agreement had been reached “in principle in recent days.”
During the same conference call, Philips reiterated its financial targets for 2026, while clarifying that these goals do not encompass other lawsuits related to Respironics or the investigations initiated by Attorneys General from various states in the U.S.
Jakobs mentioned that discussions with Attorneys General from several states are still ongoing, but he emphasized that it is too early to provide details or confirm the terms of any agreement.
While the provision of €288 million represents a significant financial commitment, for investors, this marks a move toward clarity regarding the legal uncertainties that have surrounded the company. Moreover, Philips’ strong performance in core earnings for the third quarter exceeded market expectations, which briefly boosted the stock price following the announcement.
The company reported a 7.2% growth in adjusted earnings before interest, taxes, and amortization (EBITA) to €569 million (around $637 million), surpassing analysts’ expectations of €522 million. Comparable sales increased by 3% to €4.39 billion, although this was slightly below the previous forecast of €4.41 billion.
Philips attributes its better-than-expected adjusted EBITA primarily to sales growth, improved gross margins, and enhanced productivity, factors that have effectively mitigated the impact of rising costs.
In summary, this development marks a crucial step for Philips in addressing its legal challenges, while also maintaining a focus on the overall performance and future trajectory of the company in the healthcare technology landscape.